Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm : applies for approval of Avigan as COVID-19 treatment in Japan

10/15/2020 | 10:06pm EDT

TOKYO, Oct 16 (Reuters) - Fujifilm Holdings Corp said on Friday it had applied for approval in Japan of its anti-influenza drug Avigan as a treatment for COVID-19.

The company had said in September a late-stage study of Avigan had shown reduced recovery times for COVID-19 patients with non-severe symptoms and it would seek to file for approval as early as this month. (Reporting by Chris Gallagher; Editing by Muralikumar Anantharaman)


© Reuters 2020
All news about FUJIFILM HOLDINGS CORPORATION
06/11FUJIFILM  : 'Art as an Essential Facet of Life and Community' - Fujifilm Announc..
AQ
06/09FUJIFILM  : Direct Edge Expands Capabilities, Increases Efficiencies, and Deligh..
AQ
05/31FUJIFILM  : Notice of Convocation
PU
05/27FUJIFILM  : Wako Pure Chemical launches “E484Q mutation detection kit&rdqu..
PU
05/24FUJIFILM  : Showcases Comprehensive Portfolio of Enterprise Imaging Solutions at..
AQ
05/18FUJIFILM  : Japan's Fujifilm says it can make new coronavirus variant detection ..
RE
05/18BAYER  : BlueRock, Fujifilm Cellular Dynamics to Co-Develop Cell Therapies for E..
MT
05/18FUJIFILM  : BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therape..
PU
05/17FUJIFILM  : unit launches COVID-19 detection kit for Indian, Californian variant..
RE
05/17FUJIFILM  : Wako Pure Chemical launches mutation detection kit for SARS-CoV-2 &l..
PU
More news
Financials
Sales 2021 2 179 B 19 859 M 19 859 M
Net income 2021 153 B 1 398 M 1 398 M
Net Debt 2021 170 B 1 550 M 1 550 M
P/E ratio 2021 19,9x
Yield 2021 1,26%
Capitalization 3 121 B 28 429 M 28 437 M
EV / Sales 2021 1,51x
EV / Sales 2022 1,37x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 7 840,00 JPY
Last Close Price 7 806,00 JPY
Spread / Highest target 28,1%
Spread / Average Target 0,44%
Spread / Lowest Target -20,6%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION43.55%28 429
ABBOTT LABORATORIES0.38%195 290
MEDTRONIC PLC5.67%166 534
BECTON, DICKINSON AND COMPANY-3.03%70 564
ALIGN TECHNOLOGY, INC.14.44%48 395
HOYA CORPORATION-2.59%46 812